ArticleESMO open2022

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.

E Borazanci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.